FORWARD I: A phase 3 study to evaluate the safety and efficacy of mirvetuximab soravtansine (IMGN853) versus chemotherapy in adults with folate receptor alpha (FRa)-positive, platinum-resistant epithelial ovarian cancer, primary peritoneal cancer, or primary fallopian tube cancer

被引：0
|
作者：
Moore, K. N. [1 ]
Vergote, I. [2 ]
Oaknin, A. [3 ]
Colombo, N. [4 ]
Banerjee, S. [5 ]
Oza, A. M. [6 ]
Pautier, P. [7 ]
Kelly, C. M. [8 ]
Malek, K. [9 ]
Birrer, M. J. [10 ]
机构：
[1] Univ Oklahoma, Stephenson Canc Ctr, Obstet & Gynecol, Oklahoma City, OK USA
[2] Univ Hosp Leuven, Gynaecol Verloskunde, Leuven, Belgium
[3] Vall dHebron Univ Hosp, Vall dHebron Inst Oncol VHIO, Dept Med Oncol, Barcelona, Spain
[4] Ist Europeo Oncol, Dept Gynecol Oncol, Milan, Italy
[5] Royal Marsden, Gynaecol Unit, London, England
[6] Princess Margaret Canc Ctr, Div Med Oncol & Hematol, Toronto, ON, Canada
[7] Gustave Roussy Inst Cancerol, Med Oncol, Villejuif, France
[8] Univ Coll Dublin, Mater Misericordiae Univ Hosp, Med Oncol, Dublin, Ireland
[9] ImmunoGen Inc, Clin Dev, Waltham, MA USA
[10] Massachusetts Gen Hosp, Gynecol Oncol, Boston, MA 02114 USA
来源：
ANNALS OF ONCOLOGY | 2017年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
991TiP
引用
收藏
页数：1
相关论文
共 50 条
  • [21] A phase II study of the combination chemotherapy of bevacizumab and gemcitabine in women with platinum-resistant recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer
    Shoji Nagao
    Ai Kogiku
    Kazuhiro Suzuki
    Takashi Shibutani
    Kasumi Yamamoto
    Tomoatsu Jimi
    Miho Kitai
    Takaya Shiozaki
    Kazuko Matsuoka
    Satoshi Yamaguchi
    Journal of Ovarian Research, 13
  • [22] A phase II trial of weekly docetaxel in patients with platinum-resistant epithelial ovarian, primary peritoneal serous cancer, or fallopian tube cancer
    Berkenblit, A
    Seiden, MV
    Matulonis, UA
    Penson, RT
    Krasner, CN
    Roche, M
    Mezzetti, L
    Atkinson, T
    Cannistra, SA
    GYNECOLOGIC ONCOLOGY, 2004, 95 (03) : 624 - 631
  • [23] PHASE II TRIAL EVALUATING EFFICACY AND SAFETY OF STANDARD OF CARE WITH OR WITHOUT BEVACIZUMAB IN PLATINUM-RESISTANT EPITHELIAL OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER
    Nishikawa, N.
    Shoji, T.
    Enomoto, T.
    Abe, M.
    Okamoto, A.
    Saito, T.
    Oishi, T.
    Nagase, S.
    Mori, M.
    Inokuchi, Y.
    Kamiura, S. K.
    Sugiyama, T.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2020, 30 : A10 - A11
  • [24] A multicentre phase II study of AZD1775 plus chemotherapy in patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer
    Moore, K. N.
    Cadoo, K. A.
    Chambers, S.
    Ghamande, S.
    Konecny, G.
    Oza, A. M.
    Chen, L-M.
    Konstantinopoulos, P. A.
    Lea, J.
    Spitz, D.
    Uyar, D.
    Mugundu, G.
    Laing, N.
    Strickland, D. K.
    Jones, S.
    Burris, H.
    Spigel, D. R.
    Hamilton, E.
    ANNALS OF ONCOLOGY, 2017, 28
  • [25] Phase I study of combination chemotherapy with irinotecan and gemcitabine for taxane/platinum resistant ovarian, fallopian tube, or primary peritoneal cancer
    Yoshino, Kiyoshi
    Kamiura, Shoji
    Ogawa, Haruki
    Tokuhira, Atsushi
    Takemura, Masahiko
    Sawada, Kenjiro
    Ueda, Yutaka
    Mabuchi, Seiji
    Fujita, Masami
    Tsutsui, Tateki
    Kimura, Tadashi
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [26] ARTISTRY-7: PHASE 3 MULTICENTER STUDY OF NEMVALEUKIN ALFA PLUS PEMBROLIZUMAB VERSUS CHEMOTHERAPY IN PATIENTS WITH PLATINUM-RESISTANT EPITHELIAL OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER
    Herzog, Thomas
    Hays, John
    Moore, Kathleen
    Konstantinopoulos, Panagiotis
    Gilbert, Lucy
    Monk, Bradley
    O'Malley, David
    Barlin, Joyce
    Rege, Jessicca
    Desai, Monali
    Du, Yangchun
    Dalal, Rita
    Coleman, Robert L.
    Sehouli, Jalid
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2022, 32 : A235 - A235
  • [27] Phase Ib Study of Navicixizumab Plus Paclitaxel in Patients With Platinum-Resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
    Fu, Siqing
    Corr, Bradley R.
    Culm-Merdek, Kerry
    Mockbee, Colleen
    Youssoufian, Hagop
    Stagg, Robert
    Naumann, R. Wendel
    Wenham, Robert M.
    Rosengarten, Rafael D.
    Benjamin, Laura
    Hamilton, Erika Paige
    Moore, Kathleen N.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (23) : 2568 - +
  • [28] Phase II prospective study of weekly topotecan and bevacizumab in platinum-resistant ovarian, fallopian tube or primary peritoneal cancer
    McGonigle, K. F.
    Muntz, H. G.
    Vuky, J.
    Paley, P. J.
    Veljovich, D. S.
    Gray, H. J.
    Malpass, T. W.
    GYNECOLOGIC ONCOLOGY, 2009, 112 (02) : S145 - S145
  • [29] A randomised Phase II study of phenoxodiol with platinum or taxane chemotherapy in chemoresistant epithelial ovarian cancer, fallopian tube cancer and primary peritoneal cancer
    Goss, G.
    Quinn, M.
    Rutherford, T.
    Kelly, M.
    EJC SUPPLEMENTS, 2005, 3 (02): : 261 - 261
  • [30] A phase I study of mirvetuximab soravtansine (IMGN853) and gemcitabine (G) in patients with FOLR1-positive recurrent epithelial ovarian (EOC), endometrial cancer (EC), or triple-negative breast cancer (TNBC).
    Cristea, Mihaela C.
    Frankel, Paul Henry
    Synold, Timothy W.
    Mortimer, Joanne E.
    Stewart, Daphne B.
    Wang, Edward Wenge
    Jung, Alex
    Wilczynski, Sharon P.
    Konecny, Gottfried E.
    Parungao, Dia
    Eng, Melissa
    Kilpatrick, Lindsay
    Chen, Yi-Jen
    Glaser, Scott
    Han, Ernest Soyoung
    Dellinger, Thanh Hue
    Hakim, Amy
    Lee, Stephen
    Morgan, Robert
    Wakabayashi, Mark Tsuneo
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
12345